
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. is advancing its late-stage pipeline with promising data from the FRAME and RAMP 201 trials, suggesting that its combination therapy of avutometinib and defactinib may offer significant efficacy and improved safety advantages, particularly for KRAS mutant cancers. The projected global sales potential of over $400 million for low-grade serous ovarian carcinoma (LGSOC) and $200 million for non-small cell lung cancer (NSCLC) starting as early as mid-2025 indicates a robust opportunity for revenue generation. Moreover, recent communications with management have resulted in heightened confidence in the company's trajectory, supported by a focus on effective therapeutic outcomes and the potential for the upcoming clinical milestones to drive share appreciation.
Bears say
Verastem Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the lack of substantial randomized data for its lead drug, avutometinib, raising concerns about its efficacy and safety in upcoming clinical trials. Competitive pressures could hinder patient enrollment and reduce market uptake, while the company's targeted approach may limit its market potential given the small addressable population. Additionally, if the clinical development fails to yield positive results, Verastem's stock could decline sharply, potentially trading near its net cash position with minimal value attributed to its pipeline.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares